Navigation Links
MiMedx Announces Record Second Quarter Results
Date:7/31/2013

e. The WPS coverage was effective July 1st, and we expect to see a significant impact from that during the third quarter. As we have stated previously, we have aggressively pursued this critical aspect of our reimbursement strategy, and we are very happy to see the ongoing results from that initiative," added Petit.

"We are embarking on the next phase of expansion of our direct sales force.  This phase will occur during the third quarter and will primarily focus on adding additional sales executives in our commercial wound care sales channel. The pace and location of our expansion of additional commercial wound care sales executives will be aligned with the approvals of the MACS," stated Bill Taylor, President and COO. "We also are expanding the sales staff in our government sales channel, as well as the surgical and orthopedic channel, as market opportunities dictate. At the end of the second quarter, we had 28 sales executives dedicated to our direct sales force focused on the government sector, 21 sales executives dedicated to our commercial wound care sales force and 7 sales executives in our sales force managing the surgical and orthopedic market sectors. This surgical and orthopedic sales force also manages our comprehensive network of independent sales distributors."

During the quarter, MiMedx continued its expansion of the resources focused on clinical research. In June, the randomized controlled trial (RCT) for the Company's EpiFix® wound care allograft was published electronically in the International Wound Journal.   The results of this clinical trial were compelling. The allografts were so clinically effective that extremely high statistical significance was reached quickly, and the study was concluded early. In July, the results of the crossover patients from this RCT were also published electronically in the Journal of Wound Care. The results for this treatment group were as compelling as the results for the ori
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
2. MiMedx To Exceed High End Of Second Quarter Guidance
3. MiMedx to Ring NASDAQ Stock Market Opening Bell
4. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
5. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
6. MiMedx Announces Record First Quarter 2013 Results
7. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
8. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
9. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
10. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
11. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Decision Resources Group finds that ... in the United States ... penetration will be the level of savings achievable ... expected lower cost to patients. Payers plan to ... their pricing expectations in order to encourage physician ...
(Date:7/30/2014)... July 30, 2014  Replikins Ltd. today released new ... Ebola virus. Before the current outbreaks, the mean Ebola ... amino acids) between 1995 and 2002 was 1.1; the ... 2012, and sixteen-fold in 2013, thus predicting the current ... technology has been shown to be able to predict ...
(Date:7/30/2014)... 30, 2014 Sales Horizons, a leader ... blended sales training programs for companies engaged in complex ... used by thousands of salespeople over 25 years in ... program can be customized to address the unique sales ... blended sales training program consists of two parts: ...
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... (Amex: PLX ), announced today the pricing of ... stock at a,public offering price of $5.00 per share. ... to purchase up to 1,500,000 additional shares of,common stock ... is acting as sole book-running manager for this,offering. CIBC ...
... Oct. 24 , First Quarter Highlights:, - ... - Diluted EPS up 40% to $0.35 year-over-year, excluding ... related to one-time non-U.S. net tax adjustments PAREXEL ... results for the first quarter ended September 30, 2007. ...
... The Pittsburgh Life Sciences,Greenhouse (PLSG), the private/public ... a fast track for growth, announced that ... LLC, a developmental-stage,medical device company, whose goal ... probe that will alleviate the existing,limitations of ...
Cached Biology Technology:Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 9The PLSG Invests $115,000 in Innovention Technologies, LLC 2
(Date:7/30/2014)... increase in Impact Factors for its molecular bioscience ... (Thomson Reuters, 2014) show that Clinical Science ... Biochemistry , Biochemical Society Transactions and ... their Impact Factors. The journals are owned by ... Limited. , 2014 Impact Factors (2013 Impact Factor ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... of iodine-125 (125I) in cancer treatment has been ... ganglia are critical for neural transmission between the ... and colleagues from Institute of Radiation Medicine, Chinese ... could be implanted into rat dorsal root ganglia ... seeds with different radioactivity (0, 14.8, 29.6 MBq) ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... nervous control of nematode mating behavior have produced video ... a hermaphrodite. Writing in the open access journal ... the California Institute of Technology investigated the role of ... achieve an exploratory embrace. The video shows ...
... and China have gathered in Barcelona this week to report ... data from ESA and Chinese Earth observation satellites. Dragon ... of Science and Technology (MOST) of China encourages scientists ... environmental phenomena in China. ,The symposium, held in Barcelona,s World ...
... Mo. If the growing presence of computer ,geeks, ... increasingly becoming essential tools for detecting and combating skullduggery. ... advantage of these tools. Researchers also are beginning to ... of deception, known as molecular mimicry. "Molecular ...
Cached Biology News:Europe and China watching Earth together 2Computers aid in cracking deception in plants 2
... Tissue Extract Protein Array Kit is designed ... extracts. The expression of a protein in ... specific antibody. When the antibody binds the ... sensitive chemiluminescent or fluorescent signal created by ...
... is a is a bovine protein-free alternative ... is an aqueous solution that contains non-toxic ... saline), pH 6.6 - 7.2. This ... and 0.02% bromonitrodioxane as a preservative. ...
... is an aqueous-based mounting medium designed ... sections. Gel/Mount is especially recommended when ... or FluoroBlue. It can also be ... as fluorescein (FITC), Rhodamine (TMRITC) and ...
...
Biology Products: